Diagnosis and Cure Experience of Hepatolithiasis-Associated Intrahepatic Cholangiocarcinoma in 66 Patients |
Li, Hong-Yang
(Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing University of Medical Sciences)
Zhou, Shi-Ji (Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing University of Medical Sciences) Li, Min (Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing University of Medical Sciences) Xiong, Ding (Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing University of Medical Sciences) Singh, Akanand (Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing University of Medical Sciences) Guo, Qing-Xi (Department of Pathology, Luzhou Medical College) Liu, Chang-An (Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing University of Medical Sciences) Gong, Jian-Ping (Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing University of Medical Sciences) |
1 | Palmucci S, Mauro LA, CoppolinoM, et al (2010). Evaluation of the biliary and pancre-atic systemwith 2D SSFSE, breath-hold 3D FRFSE and respiratory-triggered 3DFRFSE sequences. Radio Med, 115, 467-82. DOI |
2 | Patel T, Singh P (2007). Cholangiocarcinoma: emerging approaches toa challenging cancer. Curr Opin Gastroenterol, 23, 317-23. DOI |
3 | Patt Yz Hassan MM.Lozano RD, et al (2001). Phase II trial of cisplatin,interferon alpha-2b,doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res, 7, 3375-80. |
4 | Saness, MacCallum JD (1952). Primary carcinoma of the liver cholangiocarcinoma in hepatolithiasis. Am J pathol, 18, 675-9. |
5 | Schulick RD (2008). Primary sclerosing cholangitis: detection of cancer in strictures. J Gastrointest Surg, 12, 420-2. DOI |
6 | Shaib YH, Davila JA, Henderson L, McGlynn KA, El-Serag HB (2007). Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study. J Clin Gastroenterol, 41, 911-7. DOI |
7 | Sodickson A, Mortele KJ, BarishMA, et al (2006). Threedimensional fast-recovery fastspin-echoMRCP: comparisonwith two-dimensional single-shot fast spin-echo techniques. Radiology, 238, 549-59. DOI |
8 | Tanaka S, Yamamoto T, Tanaka H, et al (2005). Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: immunohistochemical evidence. Hepatol Res, 32, 52-7. DOI |
9 | Tischoff I, Tannapfel A (2007). Hepatocellular carcinoma and cholangiocarcinoma-different prognosis, pathogenesis and therapy. Zentralbl Chir, 132, 300-5. DOI |
10 | Chen MF, Jan YY, Hwang TL, Jeng LB, Yeh TS (2000). Impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma. Dig Dis Sci, 45, 312-6. DOI |
11 | Chen YX, Zeng ZC, Tang ZY, et al (2010). Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer, 10, 492. DOI |
12 | Choi JY, KimMJ, Lee JM, et al (2008). Magnetic resonance cholangiography: comparison of two- and three-dimensional sequences for assessment of malignant biliary obstruction. Eur Radiol, 18, 78-86. DOI |
13 | Connor S, Barron E, Redhead DN, et al (2007). Palliation for suspected unresectable hilar cholangiocarcinoma. Eur J Surg Oncol, 33, 341-5. DOI |
14 | Gaujoux S, Allen PJ (2010). Role of staging laparoscopy in peri-pancreatic and hepatobiliary malignancy. World J Gastrointest Surg, 2, 283-90. DOI |
15 | Zhou YM, Yin ZF, Yang JM, et al (2008). Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol, 14, 632-5. DOI |
16 | Uenishi T, Yamazaki O, Yamamoto T, et al (2005). Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg, 12, 479-83. DOI |
17 | Witzigmann H, Berr F, Ringel U, et al (2006). Surgical and pallia-tive management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg, 244, 230-9. DOI |
18 | Yeh TS, Tseng JH, Chen TC, et al (2005). Characterization of intrahepatic cholangiocarcinoma of the intraductal growthtype and its precursor lesions. Hepatology, 42, 657-64. DOI |
19 | Zhou YM, Yang JM, et al (2008). Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein. World J Gastroenterol, 14, 2251-4. DOI |
20 | Glockner JF (2007). Hepatobiliary MRI: current concepts and controversies. J Magn Reson Imaging, 25, 681-95. DOI |
21 | Han SL, Zhou HZ, Cheng J, et al (2009). Diagnosis and surgical treatment of intrahepatic hepatolithiasis associated cholangiocarcinoma. Asian J Surg, 32, 4-5. |
22 | Jan YY, Yeh CN, Yeh TS, et al (2005). Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol, 11, 1779-84. DOI |
23 | Kinjo N, Shimada M, Maeda T, et al (2005). Preoperatively undiagnosable intrahepatic bile duct dilatation contains early-stage intrahepatic cholangiocarcinoma. Hepatogastroenterology, 52, 1368-71. |
24 | Kuroki T, Tajima Y, Kanematsu T (2005). Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms. J Hepatobiliary Pancreat Surg, 12, 463-6. DOI |
25 | Lang H, Sotiropoulos GC, Brokalaki E, et al (2006). Surgical therapy of intrahepatic cholangiocellular carcinoma. Chirurg, 77, 53-60. DOI |
26 | Lazaridis KN, Gores GJ (2005). Cholangiocarcinoma. Gastroenterology, 128, 1655-67 DOI ScienceOn |
27 | Li YG, Zhang N (2009). Clinical significance of serum tumour M2-pk and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Livor Dis, 44, 605-8. |
28 | Morris-Stiff G, Bhati C, Olliff S, et al (2008). Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg, 25, 126-32. DOI |
29 | Paik WH, Park YS, Hwang JH, et al (2009). Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc, 69, 55-62. DOI |